An Endogenous Anti-angiogenic Protein (EAP) and its Derivatives for Treatment of Cerebral Cavernous Malformations (CCM)
Prior studies have shown that administration of recombinant EAP and/or its analogues are feasible in animal models and one Phase I testing in humans resulted in no serious adverse reactions, demonstrating that EAP-based therapies are feasible and that ultimately small molecule orally-available agents that mimic EAP may be developed to treat these patients.
Recombinant EAP, its analogues, or derivatives offer potential therapies to prevent CCM lesion development and progression.
EAP is involved in the maintenance of vascular structure and homeostasis. Researchers at UC San Diego found that upon mutation of CCM1/KRIT1 gene, EAP expression is suppressed. Replacement of EAP is a novel potential therapy for CCM disease. Moreover, recombinant fragments of EAP have been shown to be therapeutic in a mouse CCM model of the disease.
Intellectual Property Info A provisional patent has been submitted. Related Materials Tech ID/UC Case 27312/2016-214-0 Related Cases 2016-214-0
USA
